Prakruti S Rao,Senbagavalli Prakash Babu,Komala Ezhumalai,Selby Knudsen,Jayalakshmy Ramakrishnan,Noyal Joseph,Chelsie Cintron,Madolyn R Dauphinais,Prakash Babu Narasimhan,Padmini Salgame,Natasha S Hochberg,David L Hom,Scott K Heysell,Charles Robert Horsburgh,Jerrold J Ellner,Pranay Sinha,Sonali Sarkar
{"title":"Rifampin Exposure in Pregnant and Non-Pregnant Women with Tuberculosis in India.","authors":"Prakruti S Rao,Senbagavalli Prakash Babu,Komala Ezhumalai,Selby Knudsen,Jayalakshmy Ramakrishnan,Noyal Joseph,Chelsie Cintron,Madolyn R Dauphinais,Prakash Babu Narasimhan,Padmini Salgame,Natasha S Hochberg,David L Hom,Scott K Heysell,Charles Robert Horsburgh,Jerrold J Ellner,Pranay Sinha,Sonali Sarkar","doi":"10.1093/infdis/jiaf467","DOIUrl":null,"url":null,"abstract":"This prospective cohort study evaluated rifampin pharmacokinetics in pregnant and non-pregnant women with tuberculosis in India. Pregnant women had significantly lower drug exposure, with <20% of the participants achieving target concentrations at any trimester. Findings highlight potential underdosing in pregnancy and underscore the need for dedicated pharmacokinetics studies in pregnancy, and revised rifampin dosing guidelines.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf467","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This prospective cohort study evaluated rifampin pharmacokinetics in pregnant and non-pregnant women with tuberculosis in India. Pregnant women had significantly lower drug exposure, with <20% of the participants achieving target concentrations at any trimester. Findings highlight potential underdosing in pregnancy and underscore the need for dedicated pharmacokinetics studies in pregnancy, and revised rifampin dosing guidelines.